The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.